Build a Better Process
Stock Risk Measures for Dicerna Pharmaceuticals Inc
A quantitative factor review as of May 28, 2021.
- Company Info - Description, identity and sector data.
- Share Data - Stock earnings and key dates.
- Market Risk - Beta, size, liquidity and momentum measures.
- Financial Risk - Earnings and dividends.
Updated: June 01, 2021
See how we arrive at an overall risk score of
for DRNA below.
An ad-free and cookie-free website.
DRNA Risk Report
Our quantitative data points are meant to provide a high-level understanding of
factors in equity risk models for Dicerna Pharmaceuticals Inc. Portfolio managers use these
models to forecast risk, optimize portfolios and review performance.
We show how DRNA stock compares to 2,000+ US-based stocks, and to
peers in the Manufacturing sector and Pharmaceutical Preparation Manufacturing industry.
Please do not consider this data as investment advice. Data is downloaded from
sources we deem reliable, but errors may occur.
Sector and Industry
- Sector: Manufacturing
- Industry: Pharmaceutical Preparation Manufacturing
- SIC Code: 2834
- Shares Outstanding: 76,900,108
Earnings and Dividends
- Trailing 12-month earnings: -1.62
- Next earnings date: 2021-08-05
- Dividend yield in last 12 months: 0%
- Ex-dividend date:
Market Risk Measures
Many of the following risk metrics are standardized and transformed into
quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest
rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs
in the market. (↑↑)
Beta: 0.99 |
Stocks with higher market capitalization often have lower risk. (↑↓)
Market Capitalization: $2,506,943,521 |
Higher average daily dollar volume over the past 30 days implies lower
liquidity risk. (↑↓)
Daily Dollar Volume: $23,905,797 |
Higher price momentum stocks, aka recent winners, equate to lower risk for many
Stock Price Change (1-Year): 51.14% |
Financial Risk Measures
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Earnings Yield (E/P): -4.96% |
Companies with higher dividend yields, if sustaintable, are perceived to
have lower risk. (↑↓)
Dividend Yield (D/P): 0% |
DRNA stock risk
DICERNA PHARMACEUTICALS INC stock beta
DRNA risk report
DRNA risk analysis
DICERNA PHARMACEUTICALS INC credit risk
DRNA liquidity risk
DRNA systematic risk
DRNA specific risk
DICERNA PHARMACEUTICALS INC volatility
DRNA financial ratio
A newly-updated free resource. Connect and refer a friend today.